Inhibition of FOXM1 in soft tissue sarcomas has been shown to reduce tumor size in vivo (210), suggesting that targeting FOXM1 may offer a viable therapeutic strategy for CC. This evidence concerns the gene FOXM1 and soft tissue sarcoma.